1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Lynparza/Recentin Combo Fails In Phase III PSR Ovarian Cancer

Disappointment For AstraZeneca

 
• By Alexandra Shimmings

Lynparza will weather the failure of the Phase III GY004 study, but VEGF inhibitor Recentin’s future looks even less certain; other studies of the combination continue.    

Ovarian cancer
Ovarian cancer is difficult to treat • Source: Shutterstock

There is no benefit in using a combination of AstraZeneca PLC’s investigational oral VEGF receptor tyrosine kinase inhibitor, Recentin (cedirinib), and AZ/Merck & Co. Inc.’s PARP inhibitor Lynparza (olaparib) over platinum-based chemotherapy to treat patients with platinum-sensitive relapsed ovarian cancer, top-line data from the Phase III GY004 study show. The results are another disappointment for Recentin, but they should do little to dent Lynparza’s dominance of the ovarian cancer PARP inhibitor market.

The GY004 trial, led by NRG Oncology and sponsored by the US National Cancer Institute (NCI), saw no improvement in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Argenx Powers Ahead With Vyvgart’s Prefilled Syringe Launch

 
• By Andrew McConaghie

The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.

Sanofi CFO Says Direct Sales To Patients ‘Certainly Worth Considering’

 
• By Kevin Grogan

François Roger believes fixing inefficiencies is more important than playing with pricing.

Vyne Seeks Partner For Repibresib After Phase IIb Vitiligo Fail

 
• By Alaric DeArment

The Phase IIb study failed its primary and a key secondary endpoint, but showed activity on another key secondary and an exploratory endpoint.

Blenrep Questions Won’t Go Away But GSK Sees Chance To Lead In COPD

 
• By Andrew McConaghie

GSK is sticking to its guns on its forecasts for Blenrep and the firm’s total sales in 2031 despite concerns about the antibody-drug conjugate’s approvability in the US.

More from R&D